Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice

Neurochemical Research

Volumn 28, Issue 7, 2003, Pages 1017-1027

  Lemere, Cynthia A ^a,b   Spooner, Edward T ^a   Leverone, Jodi F ^a   Mori, Chica ^a   Iglesias, Melitza ^a   Bloom, Jeanne K ^a   Seabrook, Timothy J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

A ; Adjuvants; Antibodies; APP; Intranasal; PSAPP; Transgenic; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-40]; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; QS 21; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY TITER; CLINICAL TRIAL; COGNITION; DRUG EFFECT; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TRANSGENIC MOUSE; TREATMENT OUTCOME; VACCINATION; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANIMALS, WILD; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; VACCINATION;

ANIMALIA; ESCHERICHIA COLI; MUS MUSCULUS;

EID: 0037617919     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023203122036     Document Type: Review

References (61)

1. Selkoe, D. J. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
2. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
3. Hsiao, K., Chapman, P., Nilsen, S., Ekman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
4. Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. 2000. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:4050-4058.
5. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St George-Hyslop, P., and Westaway, D. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
6. Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.
7. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97-100.
8. Takeuchi, A., Irazarry, M. C., Duff, K., Saido, T. C., HsaioAshe, K., Hasagawa, M., Mann, D., Hyman, B. T., and Iwatsubo, T. 2000. Age-related amyloid β deposition in transgenic mice over-expressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157:331-339.
9. Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., and Morris, R. G. 2000. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408:975-979.
10. Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. L., Hope, C. E., Hatcher, J. M., DiCarlo, F., Gottschall, P., Morgan, D., and Arendash, G. W. 2001. Correlation between working memory deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22:377-385.
11. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vendevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D., and Seubert, P. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
12. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
13. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
14. Arendash, G. W., Gordon, M. N., Diamond, D. M., Austin, L. A., Hatcher, J. M., Jantzen, P., DiCarlo, G., Wilcock, D., and Morgan, D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: task specificity and correlations between Aβ deposition and spatial memory. DNA Cell Biol. 20:737-744.
15. Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., and Selkoe, D.J. 2000. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:567-579.
16. Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Desai, R., Hancock, W. W., Weiner, H. L., and Selkoe, D. J. 2000. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N. Y. Acad. Sci. 920:328-331.
17. Lemere, C. A., Spooner, E. T., LaFrancois, J. F., Malester, B., Mori, C., Leverone, J. F., Matsuoka, Y., DeMattos, R. B., Holtzman, D. M., Clements, J. D., Selkoe, D. J., and Duff, K. E. 2002. Evidence for peripheral clearance of Aβ following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. (in press).
18. Vehmas, A. K., Borchelt, D. R., Price, D. L., McCarthy, D., Wills-Karp, M., Peper, M. J., Rudow, G., Luyinbazi, J., Siew, L. T., and Troncoso, J. C. 2001. β-amyloid peptide vaccination results in marked changes in serum and brain Aβ levels in APPswe/PS1ΔE9 mice. as detected by SELD1-TOF-based Protein Chip technology. DNA Cell Biol. 20:713-721.
19. Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., and Wisniewski, T. 2001. Immunization with a non-toxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:439-447.
20. Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., and Golde, T. E. 2001. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:721-727.
21. Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R.B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
22. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. 2002. Reversible memory loss in a transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
23. Solomon, B., Koppel, R., Hanan, E., and Katzav, T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. U.S.A. 93:452-455.
24. Solomon, B., Koppel, R., Frenkel, D., and Hanan-Aharon, E. 1997. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 94:4109-4112.
25. Wilcock, D. M., Gordon, M. N., Ugen, K. E., Gottschall, P. E., DiCarlo, G., Dickey, C., Boyett, K. W., Jantzen, P. T., Connor, K. E., Melachrino, J., Hardy, H., and Morgan, D. 2001. Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation and congophilic plaque levels. DNA Cell Biol. 20:731-736.
26. Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. 2001. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:369-372.
27. Bacskai, B., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22:7873-7878.
28. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., and Holtzman, D. M. 2001. Peripheral anti-Aβ antibody alters CND and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:8850-8855.
29. Spooner, E. T., Desai, R., Mori, C., Leverone, J. F., and Lemere, C. A. 2002. The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol. Vaccine 21:290-297.
30. Kuper, C. F., Koornstra, P. H., Hameleers, D. M., Biewenga, J., Spit, B. J., Duijvestijn, A. M., van Breda Vriesman, P. J., and Sminia, T. 1992. The role of nasopharyngeal lymphoid tissues. Immunol. Today. 13:219-224.
31. Dickinson, B. L. and Clements, J. D. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immunol. 63:1617-1623.
32. Del Giudice, G., Pizza, M., and Rappuoli, R. 1999. Mucosal delivery of vaccines. Methods 19:148-155.
33. Cheng, E., Cardenas-Freytag, L., and Clements, J. D. 1999. The role of cAMP in mucosal adjuvanticity of Escherichia coli heatlabile enterotoxin (LT). Vaccine 18:38-49.
34. Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R., and Dougan, G. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. U.S.A. 92:1644-1648.
35. Barackman, J. D., Ott, G., and O'Hagan, T. 1999. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect. Immunol. 67:4276-4279.
36. O'Neal, C. M., Clements, J. D., Estes, M. K., and Conner, M. E. 1998. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J. Virol. 72:3390-3393.
37. Cardenas-Freytag, L., Cheng, E., Mayeux, P., Domer, J. E., and Clements, J. D. 1999. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immunol. 67:826-833.
38. Morris, C. B., Cheng, E., Thanawastien, A., and Clements, J. D. 2000. Effectiveness of intranasal immunization with HIV-gp 160 Env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT (R192G). Vaccine 18:1944-1951.
39. Gluck, U., Gebbers, J.-O., and Gluck, R. 1999. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73:7780-7786.
40. Lemere, C. A., Spooner, E. T., Leverone, J. F., Mori, C., and Clements, J. D. 2002. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol. Aging 23:991-1000.
41. Town, T., Tan, J., Sansone, N., Obregon, D., Klein, T., and Mullan, M. 2001. Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci. Lett. 307:101-104.
42. Das, P., Minidis, N., and Golde, T. 2002. Effectiveness of Aβ1-42 immunization in the Tg2576 mouse model using DNA vaccination. Neurobiol. Aging. Abstr. 411:S109.
43. Dickey, C. A., Morgan, D. G., Kudchodkar, S., Weiner, D. B., Bai, Y., Cao, C., Gordon, M. N., and Ugen, K. E. 2001. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide. DNA Cell Biol. 20:723-729.
44. Leverone, J. F., Spooner, E. T., Lehmann, H., Clements, J. D., and Lemere, C. A. 2002. Aβ1 - 15 is less immunogenic than Aβ140/42 for intranasal immunization of wild-type mice but may be effective for boosting. Vaccine. (in press online 23, Dec., 2002).
45. Schenk, D. 2002. Amyloid-β Immunotherapy for Alzheimer's disease: the end of the beginning. Nature 3:824-828.
46. Grubeck-Loebenstein, B., Blasko, I., Marx, F., and Trieb, K. 2000. Immunization with β-amyloid: could T-cell activation have a harmful effect? Trends Neurosci. 23:114.
47. Marx, F., Blasko, I., Pavelka, M., and Grubeck-Loebenstein, B. 1998. The possible role of the immune system in Alzheimer's disease. Exp. Gerontol. 33:871-881.
48. Marx, F., Blasko, I., Zisterer, K., and Grubeck-Loebenstein, B. 1999. Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production. Exp. Gerontol. 34:783-795.
49. Newman, M. J., Wu, J.-Y., Gardner, B. H., Anderson, C. A., Kensil, C. R., Recchia, J., Coughlin, R. T., and Powell, M. F. 1997. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15:1001-1007.
50. Kensil, C. R., Wu, J. Y., Anderson, C. A., Wheeler, D. A., and Amsden, J. 1998. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:41-47.
51. Alexander, J., del Guercio, M. F., Maewal, A., Qiao, L., Fikes, J., Chestnut, R. W., Paulson, J., Bundle, D. R., DeFrees, S., and Sette, A. 2002. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:1625-1633.
52. Bradney, C. P., Sempowski, G. D., Liao, H.-X., Haynes, B. F., and Staats, H. F. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunizations. J. Virol. 76:517-524.
53. Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., Tough, D., Donatelli, I., and Belardelli, F. 2002. Type IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine models. J. Immunol. 169:375-383.
54. Marinaro, M., Boyaka, P. N., Jackson, R. J., Finkelman, F. D., Kiyono, H., Jirillo, E., and McGhee, J. R. 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:114-121.
55. Kim, S. K., Ragupathi, G., Musselli, C., Choi, S. J., Park, Y. S., and Livingston, P. O. 1999. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 12:597-603.
56. Monsonego, A., Zota, V., Selkoe, D., and Weiner, H. 2002. Immunogenic aspects of amyloid-β peptide: Implications for pathogenesis and treatment of Alzheimer's disease. Neurobiol. Aging. Abstr. 503:S133.
57. Frenkel, D., Katz, O., and Solomon, B. 2000. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U. S. A. 97:11455-11459.
58. Frenkel, D., Kariv, N., and Solomon, B. 2001. Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine 19:2615-2619.
59. Poduslo, J. F. and Curran, G. L. 2001. Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport. 12:3197-3200.
60. Munch, G. and Robinson, S. R. 2002. Potential neurotoxic inflammatory responses to Abeta vaccination in humans. J. Neural Transm. 109:1081-1087.
61. Lemere, C. A., Seabrook, T. J., Iglesias, M., Mori, C., Leverone, J. F., and Spooner, E. T. 2002. Modulating amyloidbeta levels by immunotherapy: A potential therapeutic strategy for the prevention and treatment of Alzheimer's disease. In Saido, T. C. (ed), Amyloid-beta Metabolism and Alzheimer's Disease. Landes Bioscience, Georgetown, TX pp. 145-161.